BioSpace News Archive

Net sales of $2.071 billion for the fourth quarter represent an increase of 0.1% over the prior year period, and an increase of 1.6% on a constant currency basis

Company Places Additional Order of 220,000 Units to Meet Growing Demand

Achieves revenue growth in Q4 of 9% on a reported basis and 10% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% organic

Alexion Pharmaceuticals announced that the Company will host an Investor Day on Wednesday, March 20, from 8:00am to 12:30pm ET.

Eli Lilly and Company and Loxo Oncology, Inc. announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Lilly’s previously-announced tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash, or approximately $8.0 billion.

Fourth-Quarter 2018 Worldwide Sales Were $11.0 Billion, an Increase of 5 Percent, Including a 3 Percent Negative Impact from Foreign Exchange; Full-Year 2018 Worldwide Sales Were $42.3 Billion, an Increase of 5 Percent, Including a Minimal Impact from Foreign Exchange

If Approved, AJOVY will be the First and Only Anti-CGRP Treatment with Quarterly and Monthly Dosing Options in the European Union

Centene Corporation announced that it has been awarded the Centers for Medicare & Medicaid Services’ 2019 Health Equity Award for its commitment to provide equal access to quality healthcare and services for people with disabilities.

CTI BioPharma Corp. announced that the Company will withdraw its European Marketing Authorization Application for pacritinib as a treatment for myelofibrosis.

Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results on Thursday, February 14 at 4:30 p.m. ET.